FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. Described are molecular determinants of cancer response to immunotherapy, as well as systems and tools for identifying and/or characterizing cancerous tumours prone to respond to immunotherapy.
EFFECT: disclosed are the cancer response determinants for the immunotherapy.
22 cl, 80 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| METHODS OF TREATING CANCER USING ACTIVATED T-CELLS | 2016 |
|
RU2729362C2 |
| USE OF INHIBITORS OF IMMUNE CONTROL POINTS IN NEW GROWTHS OF CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2726996C1 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| ANTICANCER RNA VACCINES | 2017 |
|
RU2768829C2 |
| IMMUNE-MODIFYING PARTICLES FOR CANCER TREATMENT | 2019 |
|
RU2794261C2 |
| TYPES OF COMBINATION THERAPY FOR TREATING CANCER | 2021 |
|
RU2816314C1 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| TREATING CANCER WITH IMMUNOSTIMULANTS | 2015 |
|
RU2740288C2 |
